We are committed to push forward organoid & OoC technology in order to offer more clinically relevant 3D-cell culture models and we try to regularly publish in peer-reviewed publications.
Together with our partners we are working on the future of organoids & OoC technologies.
In partnership with Joanneum Research, we are exploring the integration of nanofiber having different functions into lab-on-chip (LoC) systems. This includes the functions as membranes and optical sensors. We are investigating the potential for storing and uniformly releasing drugs on LoC chips, revolutionizing drug delivery. Simultaneously, we are exploring the use of nanofibers as versatile elements for mixing, pumping, filtering, and as sensors, enhancing the precision of LoC systems.
A pivotal element of our project revolves around integrating the nanofiber fabrication process (electrospinning) into the mass production of LoC chips. We acknowledge that the true potential of these innovations lies in their economic feasibility at scale.
Moreover, our study emphasizes the utilization of biogenic or biodegradable materials, coupled with a comprehensive life cycle analysis spanning the entire value chain. This commitment ensures that our innovations align with a more sustainable future.
Project coordinator: JOANNEUM RESEARCH Forschungsgesellschaft mbH
Project partner: NORGANOID GmbH, Genspeed Biotech GmbH, ViennaLab Diagnostics GmbH
FFG Funding, 2023 – 2026
GM1 gangliosidosis is a rare genetic disorder, with an occurrence rate of 1 in every 100,000 to 200,000 births. It stems from mutations in the GLB1 gene, which lead to a deficiency in the beta-galactosidase enzyme, causing severe neurological impairments and, unfortunately, early mortality. The therapeutic options currently available can only decelerate the disease's progression rather than provide a cure.
In collaboration with Tcelltech, the European GM1 Foundation, NORGANOID is pioneering research into gene therapy as a promising avenue for a long-term solution to GM1 gangliosidosis. Our objective is clear: to address the disease at its genetic origin, aiming to not just halt but reverse its detrimental effects. This strategy holds particular promise when implemented early in the disease's course. Utilizing organoids derived from patients, we replicate the disease environment to gain deeper insights into the impact of beta-galactosidase enzyme deficiency. Our approach marks a shift from merely managing symptoms to targeting the underlying cause of the disease, employing cutting-edge gene therapy techniques and the latest in medical product innovation.
Project partner: Tcelltech GmbH, European GM1 Foundation
In a pioneering effort, together with our partners the Austrian Center of Industrial Biotechnology (acib) and the Medical University of Graz, we are dedicated to confronting the complex fertility challenges that impede over 10% of couples worldwide and affect countless women suffering from endometriosis. This collaboration marks a significant step forward in to understand and mitigate the barriers to fertility, leveraging our collective expertise in biotechnology and medical research.
Our approach is to create endometrial organoids, also from patients’ iPSCs, that closely mimic the natural environment of the uterus. By generating these organoids from both patients struggling with fertility issues and healthy controls, we are able to delve deep into the cellular and molecular intricacies that underpin successful pregnancy. This work is further enhanced by our utilization of NORGANOID’s sophisticated chip system, which allows for the precise simulation of the endometrial environment, offering unparalleled insights into the conditions necessary for implantation and gestation.
At the heart of our methodology is the application of omics technologies, which provide a powerful lens through which to examine the plethora of genetic, proteomic, and metabolic factors that play a role in fertility. Through these cutting-edge techniques, we aim to uncover novel biomarkers and therapeutic targets that can lead to the development of more effective treatments for those facing fertility challenges. This aspect of our work promises not only to advance our understanding of reproductive health but also to pave the way for personalized medicine in the field of fertility.
We are always looking for new collaborative research projects to engage in. Reach out to us for more information.
